Study Background, Procedures, and Efficacy/Safety Data
Cancer
SECONDARY, CANCER
We conducted a secondary analysis of the Canadian Cancer Trials Group CO.17 open-label RCT (ClinicalTrials.gov identifier: A total of 572 patients were randomly assigned. Initial results published in 2007 reported a 6-week improvement in median OS with cetuximab (6.1 months 